Myriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes

Dow Jones

2024-11-02

By Sabela Ojea

Shares of Myriad Genetics fell a day after UnitedHealthcare said it would no longer cover multi-panel genetic tests for behavioral-health diagnoses.

Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month.

Starting Jan. 1, the UnitedHealth Group unit plans to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said.

The decision affects certain UnitedHealthcare commercial plans and all UnitedHealthcare Exchange plans, the insurer said.

Myriad Genetics wasn't immediately available for comment.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

November 01, 2024 12:34 ET (16:34 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2480776831"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2480776831\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2480776831?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-02 00:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480776831","market":"hk","top_or_hot":-1,"title":"Myriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Myriad Genetics fell a day after UnitedHealthcare said it would no longer cover multi-panel genetic tests for behavioral-health diagnoses. \n</p>\n<p>\n  Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month. \n</p>\n<p>\n  Starting Jan. 1, the UnitedHealth Group unit plans to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said. \n</p>\n<p>\n  The decision affects certain UnitedHealthcare commercial plans and all UnitedHealthcare Exchange plans, the insurer said. \n</p>\n<p>\n  Myriad Genetics wasn't immediately available for comment. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 01, 2024 12:34 ET (16:34 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Myriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMyriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-02 00:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Myriad Genetics fell a day after UnitedHealthcare said it would no longer cover multi-panel genetic tests for behavioral-health diagnoses. \n</p>\n<p>\n  Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month. \n</p>\n<p>\n  Starting Jan. 1, the UnitedHealth Group unit plans to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said. \n</p>\n<p>\n  The decision affects certain UnitedHealthcare commercial plans and all UnitedHealthcare Exchange plans, the insurer said. \n</p>\n<p>\n  Myriad Genetics wasn't immediately available for comment. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 01, 2024 12:34 ET (16:34 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2480776831","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480776831","pubTimestamp":1730478840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Myriad Genetics fell a day after UnitedHealthcare said it would no longer cover multi-panel genetic tests for behavioral-health diagnoses.Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month.Starting Jan. 1, the UnitedHealth Group unit plans to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said.The decision affects certain UnitedHealthcare commercial plans and all UnitedHealthcare Exchange plans, the insurer said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MYGN":"万基遗传"},"translate_title":"UnitedHealthcare承保范围变化导致Myriad Genetics股价下跌21%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":1},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Shares of Myriad Genetics fell a day after UnitedHealthcare said it would no longer cover multi-panel genetic tests for behavioral-health diagnoses. \n\n\n  Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month. \n\n\n  Starting Jan. 1, the UnitedHealth Group unit plans to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said. \n\n\n  The decision affects certain UnitedHealthcare commercial plans and all UnitedHealthcare Exchange plans, the insurer said. \n\n\n  Myriad Genetics wasn't immediately available for comment. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 01, 2024 12:34 ET (16:34 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}